Table 3.
Predictive ability of multiple biomarkers for immunotherapy response across the external validation datasets
| Study | Number of patients | Cancer | AUC (CXCL9 + GBP5 + IFNG) | AUC (CXCL9 + IFNG) | AUC (IFNG) | AUC (PD-1) | AUC (PD-L1) | AUC (CD8A) | AUC (TMB) | AUC (TNB) |
|---|---|---|---|---|---|---|---|---|---|---|
| Nathanson et al. CTLA4 | 9 | SKCM | 1 (1) | 0.950 (2) | 0.75 (3) | 0.600 (5) | 0.650 (4) | 0.450 (6) | - | - |
| Kim et al. PD-1 | 45 | STAD | 0.843 (1) | 0.843 (1) | 0.843 (1) | 0.763 (4) | 0.833 (2) | 0.798 (3) | - | - |
| Gide et al. PD-1 | 41 | SKCM | 0.816 (5) | 0.811 (6) | 0.837 (2) | 0.849 (1) | 0.828 (3) | 0.818 (4) | - | - |
| Gide et al. PD-1 + CTLA4 | 32 | SKCM | 0.81 (1) | 0.805 (2) | 0.738 (4) | 0.658 (6) | 0.788 (3) | 0.736 (5) | - | - |
| Lauss et al. ACT | 25 | SKCM | 0.787 (1) | 0.727 (3) | 0.72 (4) | 0.687 (5) | 0.733 (2) | 0.680 (6) | - | - |
| Riaz et al. PD-1 + CTLA4 | 44 | SKCM | 0.690 (1) | 0.631 (4) | 0.603 (6) | 0.651 (3) | 0.541 (8) | 0.656 (2) | 0.574 (7) | 0.609 (5) |
| Braun et al. PD-1 | 172 | KIRC | 0.587 (1) | 0.541 (3) | 0.541 (3) | 0.496 (5) | 0.569 (2) | 0.492 (6) | 0.511 (4) | - |
| Hugo et al. PD-1 | 26 | SKCM | 0.56 (2) | 0.530 (5) | 0.542 (4) | 0.548 (3) | 0.601 (1) | 0.530 (5) | - | - |
| PUCH PD-L1 | 14 | GI | - | 0.875 (1) | 0.833 (2) | 0.792 (3) | 0.750 (4) | 0.542 (5) | - | - |
| Chen et al. CTLA4 + PD-1 | 14 | SKCM | - | 0.822 (1) | 0.8 (2) | 0.733 (3) | 0.622 (4) | 0.8 (2) | - | - |
| Chen et al. CTLA4 | 16 | SKCM | - | 0.673 (1) | 0.509 (4) | 0.582 (3) | 0.582 (3) | 0.636 (2) | - | - |
| Prat et al. PD-1 | 33 | NSLC + HNSC + SKCM | - | 0.671 (1) | 0.569 (3) | 0.635 (2) | 0.417 (4) | 0.635 (2) | - | - |
| PUCH PD-1 | 61 | GI | - | 0.653 (3) | 0.677 (2) | 0.619 (4) | 0.719 (1) | 0.585 (5) | - | - |
SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; KIRC, kidney renal clear cell carcinoma; GI, gastrointestinal cancer; NSLC, non-small cell lung cancer; HNSC, head and neck squamous cell carcinoma.